Union Health Ministry expands QR code-based drug traceability framework to vaccines, antimicrobials and anti-cancer medicines
New Delhi, June 25
In a major step towards strengthening the quality, safety and integrity of India's pharmaceutical supply chain, the Ministry of Health and Family Welfare on Thursday notified amendments to the Drugs Rules, 1945, to expand the ambit of Schedule H2 and bring additional categories of drugs under the QR Code-based track and trace framework.
According to the release, "Under the amended provisions, all vaccines, antimicrobials, narcotic and psychotropic drugs covered under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985, and all anti-cancer drugs have been included under Schedule H2 of the Drugs Rules, 1945."
With this amendment, manufacturers of these drug formulations will be required to print or affix a Bar Code or Quick Response (QR) Code on the primary packaging label of the product or, where there is inadequate space, on the secondary packaging label.
The QR Code shall store information that can be accessed through software applications to facilitate authentication and verification of the product throughout the supply chain.
The QR Code will contain key product information, including the unique product identification code, generic and brand names, name and address of the manufacturer, batch number, manufacturing and expiry dates, manufacturing licence number, and details of excipients, wherever applicable.
The requirement for QR Code-based identification was earlier applicable to the top 300 pharmaceutical brands in the country.
The present amendment significantly expands its coverage to include all vaccines, antimicrobials, anti-cancer medicines and narcotic and psychotropic drugs, thereby broadening the scope of traceability and strengthening safeguards against the circulation of counterfeit and substandard medicines.
The enhanced traceability mechanism will facilitate the authentication of medicines at various stages of the supply chain and enable improved tracking and verification of drug products. The measure is expected to strengthen regulatory oversight and support efforts to curb the distribution of spurious medicines in the market.
It will also contribute to the national fight against Anti-Microbial Resistance (AMR) by enabling better identification and monitoring of counterfeit and substandard antimicrobial products.
Recognising the need to provide adequate time to industry and other stakeholders for implementation, the Ministry has prescribed phased timelines for compliance.
The provisions relating to vaccines, narcotic and psychotropic drugs, and anti-cancer medicines shall come into force from 1 July 2027, while the provisions relating to antimicrobials shall become effective from 1 July 2028.
— ANI
Reader Comments
Great initiative by the government! The fight against fake medicines and AMR is critical. But I hope the timeline is realistic – small manufacturers, especially in Tier-2 and Tier-3 cities, will need proper support and training to implement QR codes effectively. Otherwise, it could become a compliance burden.
As someone who works in pharma logistics abroad, I can say this is a move in the right direction. India is a massive supplier of generic drugs globally, so this will also help with international trust and quality standards. The 3-4 year timeline seems reasonable for proper rollout. Good job, Indian health ministry!
Finally! As a doctor, I've seen too many cases where patients come with complications from substandard antibiotics. This QR tracking will help us verify meds right at the pharmacy. But we also need strict penalties for those who still try to fake the QR codes – criminals are smart, yaar. 😤
This is excellent news for public health! Having lived in both India and the US, I've seen how critical supply chain integrity is. The AMR angle is especially smart – tracking antimicrobials will help reduce misuse. One suggestion: make the QR data accessible through a simple mobile app for patients too, not just regulators.
A good step no doubt, but I'm slightly skeptical about the implementation. India has a history of ambitious regulations that are poorly enforced. Will there be enough inspectors and digital infrastructure to actually monitor millions of QR codes? Also, what about affordability – will this increase drug costs? Need to watch closely.
We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.